# OnCo record vrd (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/vrd/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "vrd" ;
  schema:name "VRd and Dara-VRd (myeloma induction regimens)"@en ;
  schema:alternateName "VRd"@en, "RVd"@en, "Dara-VRd"@en, "D-VRd"@en, "Isa-VRd"@en, "Dara-Rd"@en, "DRd"@en, "KRd"@en, "Dara-KRd"@en, "VMP"@en, "Dara-VMP"@en, "VCd"@en, "bortezomib-based"@en, "lenalidomide-based"@en, "CD38 antibody + PI + IMiD"@en, "PI + IMiD + dexamethasone"@en ;
  schema:description "The alphabet soup of myeloma treatment: V (bortezomib, Velcade), R (lenalidomide, Revlimid), d (dexamethasone), Dara (daratumumab), Isa (isatuximab), K (carfilzomib). Dara-VRd, a four-drug quadruplet, is now the standard first treatment for most patients."@en ;
  schema:url <https://onco.cc/terms/vrd/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment> ;
  schema:citation <https://en.wikipedia.org/wiki/Multiple_myeloma#Treatment> ;
  onco:related <https://onco.cc/terms/proteasome-inhibitor/>, <https://onco.cc/terms/imid/>, <https://onco.cc/terms/autologous-transplant/>, <https://onco.cc/terms/umrd/>, <https://onco.cc/terms/doublet-triplet/> ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:sections <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/daratumumab/> ;
  onco:trials <https://onco.cc/trials/cartitude-4/> .